Zoetis Inc. $ZTS Shares Sold by Venture Visionary Partners LLC

Key Points

• Venture Visionary Partners LLC significantly reduced its stake in Zoetis Inc. by 59.7%, leaving it with 3,679 shares valued at approximately $606,000.
• Despite the stake reduction by some investors, other institutional investors such as Portside Wealth Group LLC and Tandem Investment Advisors Inc. have increased their positions in Zoetis, indicating strong institutional interest.
• Zoetis reported $1.76 EPS for the latest quarter, exceeding expectations, and raised its guidance for FY 2025 to 6.300-6.400 EPS, with analysts predicting an average EPS of 6.07 for the current year.

Venture Visionary Partners LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 59.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,679 shares of the company's stock after selling 5,441 shares during the period. Venture Visionary Partners LLC's holdings in Zoetis were worth $606,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Portside Wealth Group LLC lifted its position in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after acquiring an additional 6,672 shares during the period. Tandem Investment Advisors Inc. raised its position in shares of Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after purchasing an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC raised its position in shares of Zoetis by 31.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after purchasing an additional 1,760 shares during the last quarter. Horizon Financial Services LLC acquired a new position in shares of Zoetis during the 1st quarter worth approximately $380,000. Finally, Sage Rhino Capital LLC raised its position in shares of Zoetis by 117.6% during the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after purchasing an additional 3,791 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.7%

Shares of NYSE ZTS opened at $156.6940 on Thursday. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The firm has a fifty day moving average of $154.27 and a 200-day moving average of $158.86. The stock has a market capitalization of $69.44 billion, a PE ratio of 26.97, a P/E/G ratio of 2.50 and a beta of 0.88. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ZTS shares. UBS Group cut their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Finally, Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $202.43.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.